Targeting treatment-resistant ovarian cancer
Targeting chemotherapy resistant high grade serous ovarian cancer
['FUNDING_OTHER'] · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · NIH-10908705
This study is looking at how a protein called LIF makes high-grade serous ovarian cancer cells resistant to chemotherapy, and it aims to find ways to block this protein so that treatments can work better for patients facing this tough cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCIENCE CENTER (nih funded) |
| Locations | 1 site (SAN ANTONIO, UNITED STATES) |
| Trial ID | NIH-10908705 on ClinicalTrials.gov |
What this research studies
This research focuses on high-grade serous ovarian cancer, which is known for its high mortality rate and resistance to chemotherapy. The study investigates the role of a cytokine called leukemia inhibitory factor (LIF) and its receptor in promoting chemotherapy resistance in ovarian cancer cells. By using advanced techniques like CRISPR and genomic approaches, the research aims to disrupt LIF signaling to make resistant cancer cells more responsive to chemotherapy. The ultimate goal is to develop new therapeutic strategies that could improve treatment outcomes for patients with this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with high-grade serous ovarian cancer who have experienced chemotherapy resistance.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with chemotherapy-resistant ovarian cancer.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
SAN ANTONIO, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCIENCE CENTER — SAN ANTONIO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EBRAHIMI, BEHNAM — UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
- Study coordinator: EBRAHIMI, BEHNAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.